公开(公告)号：US20250082842A1

公开(公告)日：2025-03-13

申请号：US18883710

申请日：2024-09-12

Applicant: INSULET CORPORATION

Inventor： John BUSSIERE ,  Joon Bok LEE ,  Yibin ZHENG ,  Ashutosh ZADE ,  Jason O’CONNOR

IPC: A61M5/142 ,  A61M5/172

Abstract: In an aspect, an adhesive patch is presented. The adhesive patch has a top surface configured to adhere to a wearable medical device. The adhesive patch has a bottom surface opposite the top surface, wherein the bottom surface includes an adhesive layer configured to adhere to a user's skin. The adhesive patch has a first perforation extending through the top and bottom surfaces, the first perforation configured to receive a piercing element from the wearable medical device.

公开(公告)号：US20250025631A1

公开(公告)日：2025-01-23

申请号：US18909572

申请日：2024-10-08

Applicant: INSULET CORPORATION

Inventor： James GRAHAM ,  Joon Bok LEE ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61B5/00 ,  A61B5/145 ,  A61B5/1495 ,  A61M5/142 ,  A61M5/168 ,  G16H10/60 ,  G16H20/00 ,  G16H20/10 ,  G16H20/17 ,  G16H40/67

Abstract: Disclosed are techniques and a device operable to determine a total amount of insulin delivered to the user over a predetermined time period. The total amount of insulin includes a total basal dosage delivered in basal dosages and a total bolus dosage delivered in bolus dosages over the predetermined time period. A proportion of the total amount of insulin delivered to the user provided via the total basal dosage amount over the predetermined time period is calculated. In response determining the proportion of the total amount of insulin attributed to the total basal dosage amount of insulin exceeds a threshold, an average basal dosage to be delivered within a subsequent time period that is approximately equal to the threshold may be determined. An instruction may be generated and output to deliver a modified basal dosage that substantially maintains the average basal dosage over the subsequent time period.

公开(公告)号：US20240197990A1

公开(公告)日：2024-06-20

申请号：US18530449

申请日：2023-12-06

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  James CAUSEY ,  Ashutosh ZADE ,  Jason O’CONNOR

IPC: A61M5/172

CPC classification number: A61M5/1723 ,  A61M2205/70 ,  A61M2230/201

Abstract: Compensation may be provided for the varying accuracy levels of a sensor over time. As a result of the compensation, the medicament delivery device may perform better. The sensor may provide input to a medicament delivery device, and the input may be used to determine a dose of medicament to be delivered to a user by the medicament delivery device. A degree of inaccuracy of sensor values may be determined based on when in the lifetime a sensor value is generated. Glucose level values read by a glucose monitor, such as a CGM, may be directly modified before being used by an automated insulin delivery (AID) control of an insulin delivery device. The compensation for the inaccuracy of the glucose level values from the glucose monitor instead may be achieved by modifying a weight coefficient of a glucose cost component of a cost function in one example.

公开(公告)号：US20240009393A1

公开(公告)日：2024-01-11

申请号：US18474566

申请日：2023-09-26

Applicant: INSULET CORPORATION

Inventor： Steven CARDINALI ,  Joon Bok LEE ,  Jason O'CONNOR ,  Yibin ZHENG

IPC: A61M5/172 ,  G16H20/17 ,  G16H10/60 ,  A61B5/145

CPC classification number: A61M5/1723 ,  G16H20/17 ,  G16H10/60 ,  A61B5/14532 ,  G16H15/00

Abstract: Disclosed are a system, methods and computer-readable medium products that provide bolus dosage calculations by a control algorithm-based drug delivery system that provides automatic delivery of a drug, such as insulin or the like, based on sensor input. Blood glucose measurement values may be received at regular time intervals from a sensor. Using the blood glucose measurements, the control algorithm may perform various calculations and determinations to provide an appropriate bolus dosage. The appropriate bolus dosage may be used to respond to a trend in a trajectory of blood glucose measurements. In addition, a bolus dosage may also be determined by the disclosed device, system, method and/or computer-readable medium product in response to an indication that a user consumed a meal.

公开(公告)号：US20230381414A1

公开(公告)日：2023-11-30

申请号：US18323538

申请日：2023-05-25

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Jason O'CONNOR ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/172 ,  G16H10/60 ,  G16H20/17

CPC classification number: A61M5/1723 ,  G16H20/17 ,  G16H10/60

Abstract: Disclosed are techniques, devices and systems that obtain a glucose measurement history and a liquid drug delivery history. An expected drug delivery amount may be calculated based on the obtained glucose measurement history and the obtained liquid drug delivery history. A processor may calculate a plurality of respective drug delivery amounts implemented using different advisory mode algorithms. A respective advisory drug delivery amount of the plurality of respective advisory drug delivery amounts may be selected by the processor. A recommendation may be generated based on the selected respective advisory drug delivery amount.

公开(公告)号：US20230377706A1

公开(公告)日：2023-11-23

申请号：US18199641

申请日：2023-05-19

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Ashutosh ZADE ,  William WHITELEY ,  Jason O’CONNOR

IPC: G16H20/10 ,  A61B5/145 ,  A61B5/00 ,  G16H40/63

CPC classification number: G16H20/10 ,  A61B5/14532 ,  A61B5/4839 ,  G16H40/63

Abstract: The exemplary embodiments may dynamically adjust an Insulin on Board (JOB) profile for a user of a medicament delivery system to customize the IOB profile to the user based on recent glucose level history and insulin deliveries rather than use the conventional static IOB profiles that are based on population averages. The exemplary embodiments may calculate a Duration of Insulin Action (DIA) for a user from the customized insulin decay curves. The exemplary embodiments may generate and send notifications to the user to help reduce the DIA of the user and/or to keep the DIA of the user from rising. The exemplary embodiments may aim to not overly constrain insulin delivery due to the contribution of insulin boluses to JOB.

公开(公告)号：US20220395638A1

公开(公告)日：2022-12-15

申请号：US17839647

申请日：2022-06-14

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Ashutosh ZADE ,  Jason O'CONNOR

IPC: A61M5/172

Abstract: The disclosed embodiments are directed to methods for adjusting, on a per individual basis, the maximum delivery limit of insulin delivered to a diabetic person via an automatic insulin delivery system, particularly for a diabetic who receives basal or bolus doses of insulin via an automatic insulin delivery system. Various embodiments of the method disclosed herein may be incorporated into a dosing algorithm of an automatic insulin delivery system.

公开(公告)号：US20220361812A1

公开(公告)日：2022-11-17

申请号：US17736380

申请日：2022-05-04

Applicant: Insulet Corporation

Inventor： Rangarajan NARAYANASWAMI ,  Yibin ZHENG ,  Jay JANTZ ,  Joon Bok LEE

IPC: A61B5/00 ,  G16H20/17 ,  G16H10/60 ,  G16H50/20 ,  G16H50/50 ,  A61M5/172 ,  A61B5/145

Abstract: The disclosed embodiments are directed to systems and methods for providing optimized, individualized bolus dosing of insulin based on a macronutrient profile of meals ingested by the patient. Optimized bolus dosing may be provided by varying the overall quantity of insulin delivered in the post-prandial window, as well as the split between a portion of the insulin delivered immediately after the meal and a portion of the insulin delivered later in the post-prandial window, based on an analysis of the macronutrient profile of the meal and the behavior of the blood glucose trace of the patient from past meals.

公开(公告)号：US20220331519A1

公开(公告)日：2022-10-20

申请号：US17718663

申请日：2022-04-12

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61B5/145 ,  A61B5/1495 ,  A61M5/142 ,  G16H40/40

Abstract: Exemplary embodiments may compensate for loss of calibration by sensors that provide sensed analyte measurements to delivery devices. The exemplary embodiments may obtain one or more calibrated analyte measurements, such as by using techniques to obtain that the analyte measurement value that are known to produce properly calibrated analyte values. The one or more calibrated analyte measurements are compared to a recent analyte measurement to determine a negative or positive offset. The offset may be added to the recent analyte measurement to generate an updated analyte measurement that reflects the calibrated analyte measurement. In addition, past analyte measurement values within a time window may be updated as well by adding the offset to the past analyte measurement values. The exemplary embodiments may also compensate for the past over-delivery or under-delivery of an agent by the delivery device due to the loss of calibration.

公开(公告)号：US20220288311A1

公开(公告)日：2022-09-15

申请号：US17687808

申请日：2022-03-07

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61B5/145 ,  A61B5/00 ,  G16H20/17

Abstract: Exemplary embodiments may modify the cost function parameters based on current and projected mean outcomes in blood glucose level control performance. The exemplary embodiments may modify the weight coefficient R for the insulin cost so that the value of R is not fixed and is not based solely on clinical determined values. Exemplary embodiments may also adjust the cost function to address persistent low-level blood glucose level excursions for users. The exemplary embodiments may reduce the penalty of the insulin cost by the sum of the converted insulin cost of the glucose excursions above target for a period divided by a number of cycles of average insulin action time. The AID system reduces the insulin cost by the lack of insulin in previous cycles.